Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.

Publication Title

Blood Neoplasia

Authors

• James M Foran
• Zhuoxin Sun
• Selina M Luger
• David F Claxton
• Hillard M Lazarus
• Daniel A Arber
• Jacob M Rowe
• Elisabeth Paietta
• Janis Racevskis
• Fran Garrett-Bakelman
• Yanming Zhang
• Jessica K Altman
• Aref Al-Kali
• Hong Zheng
• Keith W Pratz
• E Randolph Broun
• Bayard L Powell
• Kristen Marie O'Dwyer
• John E Godwin, Providence Portland Medical Center, Portland, OR USA
• Yishai Ofran
• Mark R Litzow
• Martin S Tallman

Document Type

Article

Publication Date

5-1-2026

Keywords

oregon; portland; ppmc

Abstract

Clofarabine is a second-generation purine nucleoside analog with encouraging reported 30-day induction mortality (IM) and complete remission (CR) or CRi (incomplete platelet recovery) rates, and represents a lower-intensity therapy for older adults with acute myeloid leukemia (AML). We evaluated long-term outcomes in a prospective phase 3 study using a noninferiority design. Patients aged ≥60 years with newly diagnosed AML and normal renal and cardiac function were randomized to standard intensive daunorubicin and cytarabine or single-agent clofarabine. The primary objective was overall survival (OS) using a weighted analysis. We incorporated prospective central testing for measurable residual disease (MRD; ≥0.1%) at remission using multiparameter flow cytometry. Among 727 patients (standard, n = 363; clofarabine, n = 364), there was no difference in CR/CRi (50%) or IM (8.5%) rates. The median follow-up was 58.6 months. In the primary analysis, OS was inferior with clofarabine (median, 10.4 vs 12.4 months [standard]; P = .04), although not in patients aged ≥70 years, with secondary AML, or unfavorable cytogenetics. Allogeneic transplantation was strongly associated with OS on multivariate analysis (HR, 0.53; P < .0001). MRD-negative remission was achieved in 41% of patients and strongly associated with 5-year OS irrespective of treatment (MRD-positive, 48.8% vs 12.2%; P = .003). In contrast, MRD-positive patients assigned to clofarabine (vs high-dose cytarabine) consolidation had significantly inferior OS. Clofarabine is inferior to standard intensive therapy despite similar remission rates. Achieving MRD-negative remission is associated with high, sustained rates of OS regardless of therapy. Increasing MRD negativity and improving outcomes among MRD-positive patients remain pressing, ongoing challenges. This trial was registered at www.clinicaltrials.gov as NCT02085408.

Area of Special Interest

Cancer

Specialty/Research Institute

Oncology

Specialty/Research Institute

Hematology

Specialty/Research Institute

Pharmacy

DOI

10.1016/j.bneo.2026.100194